Lantern Pharma Inc.: 10-K filed 2023-03-20

Name: Lantern Pharma Inc.: 10-K filed 2023-03-20
Creator: Lantern Pharma Inc.

What Lantern Pharma Inc. reported in its annual report filed 2023-03-20 (fiscal FY 2022): 33 published measures, 66 facts as tagged in accession 0001493152-23-008241.

This filing

Form: 10-K (annual report)
Filed: 2023-03-20
Fiscal period: fiscal FY 2022
Accession: 0001493152-23-008241 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lantern Pharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-12-31	58,836,321	USD
At 2021-12-31	73,950,477	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-12-31	2,798,297	USD
At 2021-12-31	2,379,057	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-12-31	56,038,024	USD
At 2021-12-31	71,571,420	USD
At 2020-12-31	19,698,795	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-12-31	37,201,786	USD
At 2021-12-31	51,524,295	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-14,259,946	USD	365
2021-01-01 to 2021-12-31	-12,363,029	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-12,767,492	USD	365
2021-01-01 to 2021-12-31	-10,591,543	USD	365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	27,844	USD	365
2021-01-01 to 2021-12-31	15,499	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-2,182,498	USD	365
2021-01-01 to 2021-12-31	63,416,122	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	179,268	USD	365
2021-01-01 to 2021-12-31	-19,530,586	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-12-31	-39,282,870	USD
At 2021-12-31	-25,022,924	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	10,850,579	shares	365
2021-01-01 to 2021-12-31	10,904,927	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-1.31	USD/shares	365
2021-01-01 to 2021-12-31	-1.13	USD/shares	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2022-12-31	48,008	USD
At 2021-12-31	30,245	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	1,187,745	USD	365
2021-01-01 to 2021-12-31	961,545	USD	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-14,432,753	USD	365
2021-01-01 to 2021-12-31	-12,591,508	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-12-31	58,722,737	USD
At 2021-12-31	72,716,400	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-12-31	2,798,297	USD
At 2021-12-31	2,326,167	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	2,482,286	USD	365
2021-01-01 to 2021-12-31	939,666	USD	365

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	14,432,753	USD	365
2021-01-01 to 2021-12-31	12,591,508	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	8,602,954	USD	365
2021-01-01 to 2021-12-31	7,570,580	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-12-31	10,857,040	shares
At 2021-12-31	11,088,835	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-12-31	95,691,194	USD
At 2021-12-31	96,685,924	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2022-12-31	-371,386	USD
At 2021-12-31	-92,689	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2022-12-31	47,687	USD
At 2021-12-31	185,943	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2022-12-31	52,890	USD
At 2021-12-31	204,948	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2022-12-31	17,889	USD
At 2021-12-31	17,889	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2022-12-31	2,985,472	USD
At 2021-12-31	1,990,953	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2022-12-31	3,660	USD
At 2021-12-31	5,054	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-14,538,643	USD	365
2021-01-01 to 2021-12-31	-12,455,718	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	5,829,799	USD	365
2021-01-01 to 2021-12-31	5,020,928	USD	365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	10,081	USD	365
2021-01-01 to 2021-12-31	6,761	USD	365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2022-01-01 to 2022-12-31	-31,548	USD	365
2021-01-01 to 2021-12-31	160,550	USD	365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2021-01-01 to 2021-12-31	68,999,994	USD	365

Inspect the source

Entity: Lantern Pharma Inc. / CIK 0001763950
Captured: 2026-09-21T17:26:28.194Z
SEC response SHA-256: de4123361405efcd0291343ed94db7c24d43e6c36dbcd4d45ba588f463c7f9d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001763950.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))